Eli Lilly to study weight loss candidate for chronic low back pain in phase 3

Furthermore, Eli Lilly has actually selected to take out an FDA application. It worries making use of Trizepatide for the therapy of cardiac arrest in overweight people.

发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/eli-lilly-to-study-weight-loss-candidate-for-chronic-low-back-pain-in-phase-3-2/

(0)
上一篇 3 5 月, 2025 9:18 下午
下一篇 3 5 月, 2025

相关推荐

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注

联系我们

400-800-8888

在线咨询: QQ交谈

邮件:admin@example.com

工作时间:周一至周五,9:30-18:30,节假日休息

关注微信
社群的价值在于通过分享与互动,让想法产生更多想法,创新激发更多创新。